Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience

Autor: Dimosthenis Skarlos, E. Efstathiou, H. P. Kalofonos, Dimitrios Farmakis, George Fountzilas, Evangelos Briasoulis, Emmanouel Salamalekis, Meletios A. Dimopoulos, Gerasimos Aravantinos, Theofanis Economopoulos, Dimitrios Pectasides
Rok vydání: 2004
Předmět:
Oncology
Adult
Cisplatin/administration & dosage/*therapeutic use
medicine.medical_specialty
Carboplatin/administration & dosage/*therapeutic use
Cyclophosphamide
Paclitaxel
medicine.medical_treatment
Context (language use)
Ovarian Neoplasms/*drug therapy/pathology/surgery
Carboplatin
chemistry.chemical_compound
Paclitaxel/administration & dosage
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Stage (cooking)
Survival rate
Aged
Neoplasm Staging
Retrospective Studies
Ovarian Neoplasms
Chemotherapy
business.industry
Obstetrics and Gynecology
Middle Aged
medicine.disease
Adenocarcinoma
Mucinous
Combined Modality Therapy
Survival Rate
Treatment Outcome
chemistry
Adenocarcinoma
Mucinous/*drug therapy/pathology/surgery
Adenocarcinoma
Female
Cisplatin
business
Epirubicin
medicine.drug
Zdroj: Gynecologic oncology. 97(2)
ISSN: 0090-8258
Popis: Purpose. Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stage III and IV OCCC and serous EOC (sEOC). Patients and methods. A retrospective analysis was performed in patients with advanced stage of OCCC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 1/2/1987 and 31/10/2003. The outcome was compared to that of patients with sEOC treated according to the same protocols during the same study period. Results. One hundred and five patients (35 stage III and IV OCCC, 70 stage III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for OCCC was 45% (complete response 25%) (95% CI, 23.1% to 68.5%) and 81% (complete response 46%) (95% CI, 67.4% to 91.1%) for sEOC. The overall response rate was significantly higher for sEOC ( P = 0.008). In the subgroup of stage III patients, the rate of complete responders was higher among sEOC patients ( P = 0.023). After a median follow-up of 61.1 months, median survival and time to tumor progression were not significantly different between the two groups (25.1 months [95% CI 11.7 to 38.5 months] versus 49.1 months [95% CI 36.5 to 61.6 months], P = 0.141, 12.0 months [95% CI 6.5 to 17.3 months] versus 18.0 months [95% CI 14.7 to 21.6 months], P = 0.384, respectively). Conclusion. Patients with OCCC have significantly lower response to platinum-based first-line chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in significantly shorter survival. The current study outcomes are provocative and suggest that a new strategy for chemotherapy in OCCC should be adopted, possibly one that focuses on new agents without cross-resistance to platinum agents.
Databáze: OpenAIRE
Externí odkaz: